PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-21.01%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.76%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth less than half of RVPH's 25342.86%. David Dodd would verify if efficiency is sustainable.
10.97%
EBITDA growth below 50% of RVPH's 58.32%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth below 50% of RVPH's 58.36%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Other expenses growth less than half of RVPH's 385.30%. David Dodd would verify if advantage is sustainable.
11.35%
Pre-tax income growth below 50% of RVPH's 207.65%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense growth while RVPH reduces burden. John Neff would investigate differences.
11.35%
Net income growth below 50% of RVPH's 207.37%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS growth below 50% of RVPH's 851.45%. Michael Burry would check for structural issues.
31.72%
Diluted EPS growth below 50% of RVPH's 851.45%. Michael Burry would check for structural issues.
29.31%
Share count increase while RVPH reduces shares. John Neff would investigate differences.
29.44%
Diluted share increase while RVPH reduces shares. John Neff would investigate differences.